Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway

被引：0
|
作者：
Amanda Hansson-Hedblom
Isabelle Axelsson
Lena Jacobson
Joakim Tedroff
Fredrik Borgström
机构：
[1] Quantify Research AB,
[2] Allergan Norden AB,undefined
[3] Neuroenheten Utsikten,undefined
来源：
The Journal of Headache and Pain | 2020年 / 21卷
关键词：
Migraine; Headache; onabotulinumtoxinA; Botox; Cost-effectiveness; Cost of illness; Burden;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Cost-effectiveness of treatment with etanercept for psoriasis in Sweden
    Christopher Knight
    Josephine Mauskopf
    Mats Ekelund
    Amitabh Singh
    Shiyi Yang
    Robert Boggs
    The European Journal of Health Economics, 2012, 13 : 145 - 156
  • [42] Effectiveness of onabotulinumtoxinA (BOTOX®) for the preventive treatment of chronic migraine: A meta-analysis on 10 years of real-world data
    Lanteri-Minet, Michel
    Ducros, Anne
    Francois, Clement
    Olewinska, Elzbieta
    Nikodem, Mateusz
    Dupont-Benjamin, Laure
    CEPHALALGIA, 2022, 42 (14) : 1543 - 1564
  • [43] 10 Year follow up on 337 patients receiving OnabotulinumtoxinA (Botox) for Chronic Migraine, data from the Hull (UK) Migraine Clinic
    Khan, Rafiullah
    Delrosario, Helen
    Khalil, Modar
    Dorsey, Sophie
    Ijaz, Aamir
    Ahmed, Fayyaz
    CEPHALALGIA, 2023, 43 (1supp)
  • [44] Assessment of the relative effectiveness of erenumab compared with onabotulinumtoxinA for the prevention of chronic migraine
    Mahon, Ronan
    Vo, Pamela
    Pannagl, Katharina
    Tiwari, Santosh
    Heemstra, Harald
    Ferraris, Matias
    Zhao, Jing
    Betts, Keith A.
    Proot, Pascal
    CURRENT MEDICAL RESEARCH AND OPINION, 2023, 39 (01) : 105 - 112
  • [45] Modeling the Cost-Effectiveness of Successive Preventive Oral Medication Trials in Chronic Migraine
    Ney, J.
    Guirguis, A.
    Dao, V
    Sico, J.
    HEADACHE, 2023, 63 : 195 - 196
  • [46] COST-EFFECTIVENESS OF BOCEPREVIR IN THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 1 IN SWEDEN
    Chhatwal, J.
    Lundberg, J.
    Ferrante, S.
    El Khourhy, A. C.
    Oksanen, A.
    Elbasha, E. H.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S386 - S387
  • [47] Cost-effectiveness and cost-benefit of sumatriptan in patients with migraine
    Lofland, JH
    Kim, SS
    Batenhorst, AS
    Johnson, NE
    Chatterton, ML
    Cady, RK
    Kaniecki, R
    Nash, DB
    MAYO CLINIC PROCEEDINGS, 2001, 76 (11) : 1093 - 1101
  • [48] Real-world economic impact of onabotulinumtoxina in patients with chronic migraine
    JF Rothrock
    LM Bloudek
    TT Houle
    D Andress-Rothrock
    C Hanlon
    SF Varon
    The Journal of Headache and Pain, 2013, 14
  • [49] Real-World Economic Impact of OnabotulinumtoxinA in Patients With Chronic Migraine
    Rothrock, John F.
    Bloudek, Lisa M.
    Houle, Timothy T.
    Andress-Rothrock, Diane
    Varon, Sepideh F.
    HEADACHE, 2014, 54 (10): : 1565 - 1573
  • [50] Real-World Economic Impact of OnabotulinumtoxinA in Patients with Chronic Migraine
    Rothrock, John
    Bloudek, Lisa
    Houle, Timothy
    Andress-Rothrock, Diane
    Hanlon, Christopher
    Varon, Sepideh
    NEUROLOGY, 2012, 78
12345